

# Special Issue

## Monoclonal Antibodies

### Message from the Guest Editor

Monoclonal antibodies are established in clinical practice for the treatment of cancer, and autoimmune and infectious diseases. The first generation of antibodies has been dominated by classical IgG antibodies, however, in the last decade, the field has advanced, and, nowadays, a large proportion of antibodies in development have been engineered. This Special Issue on "Monoclonal Antibodies" will cover original manuscripts and reviews in the field of the development of classical monoclonal antibodies that address novel biology, as well as progress in the engineering of novel antibody formats, including antibody drug conjugates, bispecific antibodies, and antibody-like scaffolds.

---

### Guest Editor

Dr. Christian Klein

Roche Pharma Research & Early Development, Roche Innovation Center Zurich, Schlieren, Switzerland

---

### Deadline for manuscript submissions

closed (31 October 2017)



## Antibodies

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 7.1  
Indexed in PubMed



[mdpi.com/si/9311](https://mdpi.com/si/9311)

*Antibodies*

MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[antibodies@mdpi.com](mailto:antibodies@mdpi.com)

[mdpi.com/journal/  
antibodies](https://mdpi.com/journal/antibodies)





# Antibodies

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.0  
CiteScore 7.1  
Indexed in PubMed



[mdpi.com/journal/  
antibodies](https://mdpi.com/journal/antibodies)



## About the Journal

### Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

---

### Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry, Technical University of Munich, Emil-Erlenmeyer-Forum 5, 85354 Freising (Weihenstephan), Germany

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

CiteScore - Q2 (Drug Discovery)